MYCOF - Mydecine files for new patent for MDMA-like compounds

Mydecine Innovations (MYCOF) has filed a new patent for MDMA-like compounds further expanding its robust portfolio of novel compounds.The patent will allow Mydecine to scale its coverage in drug development research and FDA-approval progress for novel therapeutics.With the filed patent on entactogenic compounds, the company would be able to further develop treatments that precisely match the needs of medical practice, by reducing harm and improving the safety profile when compared to traditional MDMA.The company also highlighted that it is scaling proprietary research and development methods in order to become one of the first to produce and bring to market psilocybin-based treatments.

For further details see:

Mydecine files for new patent for MDMA-like compounds